FDA OKs Pembrolizumab for Adjuvant Treatment of NSCLC
The US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in the adjuvant setting for patients with stage IB-IIIA non–small ...
© Medical News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.